Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841854 | 0.85 | MAPT (0.61) | MAPTALDH1A1NPSR1SMN1; SMN2TP53 | |
| SCHEMBL6611537 | 0.85 | MAPT (0.45) | POLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5841187 | 0.85 | SMN1; SMN2 (0.59) | MAPTALDH1A1NPSR1SMN1; SMN2GAA | |
| SCHEMBL5841070 | 0.84 | MAPT (0.56) | POLBMAPTALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL5842030 | 0.83 | MAPT (0.64) | MAPTALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL5842505 | 0.83 | MAPT (0.64) | MAPTALDH1A1NPSR1SMN1; SMN2TP53 | |
| SCHEMBL5843367 | 0.83 | MAPT (0.62) | MAPTALDH1A1NPSR1SMN1; SMN2TP53 | |
| SCHEMBL5842097 | 0.82 | MAPT (0.61) | POLBMAPTALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL5841451 | 0.82 | ALDH1A1 (0.69) | POLBMAPTALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL5843721 | 0.81 | MAPT (0.63) | MAPTALDH1A1NPSR1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | claimed |
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | POLB 4023/4885MAPT 4395/4885ALDH1A1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.